Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT)

Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT) ANAVEX®2-73 Extends Survival and Reduces Seizures in an Orphan Disease Model NEW YORK – March 7, 2018 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics…